Support women in science at Burnet Institute
Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Eliminate Viral Hepatitis, 2023 (10)
April, 2023 (2)
- Immediate treatment for recent hepatitis C infection in people with high-risk behaviors: a systematic review and meta-analysis.
Manoharan L, Latham NH, Munari SC, Traeger MW, Menon V, Luhmann N, Baggaley R, Macdonald V, Verster A, Siegfried N, Matthews GV, Stoové M, Hellard ME, Doyle JS
Hepatol Commun. 2023 Apr; 7(4) - Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ, Boyd A, Sacks-Davis R, van Santen DK, Smit C, Martinello M, Stoové M, Berenguer J, Wittkop L, Klein MB, Rauch A, Salmon D, Lacombe K, Stewart A, Schinkel J, Doyle JS, Hellard M, van der Valk M, Matthews GV; InCHEHC study group.
Lancet Public Health. 2023 Apr; 8(4):e294-e304
March, 2023 (3)
- Assessment of a primary care e-support package of automated case finding, simplified treatment algorithm and decision support to increase hepatitis B treatment uptake in primary care clinics in Australia (SIMPLY-B Study): protocol for a pilot evaluation.
Moussa D, Wallace J, Manski-Nankervis JA, Doyle JS, Nguyen L, Boyle D, Stoové MA, Asselin J, Valaydon Z, Ahad M, Glasgow S, New K, Hocking JS, Sanci L, Thompson A, Hellard M, Howell J
BMJ Open. 2023 Mar; 13(3):e070663 - Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
MacIsaac MB, Whitton B, Hubble A, Cogger S, Penn M, Weeks A, Elmore K, Pemberton D, Anderson J, Howard R, McKeever U, Papaluca T, Hellard ME, Stoové M, Wilson D, Pedrana A, Doyle J, Clark N, Holmes J, Thompson AJ
Med J Aust. 2023 Mar; Epub ahead of print - Consensus recommendations on the management of hepatitis C in Australia's prisons.
Winter RJ, Sheehan Y, Papaluca T, Macdonald GA, Rowland J, Colman A, Stoové M, Lloyd AR, Thompson AJ
Med J Aust. 2023 Mar; 218(5):231-237
February, 2023 (1)
- Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019.
van Santen DK, Sacks-Davis R, Stewart A, Boyd A, Young J, van der Valk M, Smit C, Rauch A, Braun DL, Jarrin I, Berenguer J, Lazarus JV, Lacombe K, Requena MB, Wittkop L, Leleux O, Salmon D, Bonnet F, Matthews G, Doyle JS, Spelman T, Klein MB, Prins M, Asselin J, Stoové MA, Hellard M; InCHEHC study group.
EClinicalMedicine. 2023 Feb; 56:101810
January, 2023 (4)
- Validation of a novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study.
Howell J, Van H, Pham MD, Sawhney R, Li F, Bhat P, Lubel J, Kemp W, Bloom S, Majumdar A, McCaughan GW, Hall S, Spelman T, Doyle JS, Hellard M, Visvanathan K, Thompson A, Drummer HE, Anderson D
Liver Int. 2023 Jan; Epub ahead of print - Patient reported outcomes during and following HCV direct-acting antiviral treatment among people who inject drugs.
Cheng Q, Cunningham EB, Shih S, Amin J, Bruneau J, Artenie AA, Powis J, Litwin AH, Cooper C, Dalgard O, Hellard M, Bruggmann P, Marks P, Lacombe K, Stedman C, Read P, Hajarizadeh B, Dunlop AJ, Conway B, Feld JJ, Dore GJ, Grebely J; SIMPLIFY and D3FEAT study groups
Value Health. 2023 Jan; Epub ahead of print - The freighted social histories of HIV and hepatitis C: exploring service providers' perspectives on stigma in the current epidemics.
Valentine K, Smith A, Persson A, Gray R, Bryant J, Hamilton M, Wallace J, Drysdale K, Newman CE
Med Humanit. 2023 Jan; 49(1):48-54 - Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden. (Recommendations for hepatitis care in drug users.)
Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; im Namen vom International Network on Hepatitis care in Substance Users.
Int J Drug Policy. 2023 Jan; 111:101670
Year
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
- 1998
- 1997
- 1996
- 1995
- 1994
- 1993
- 1992
- 1991
- 1990
- 1989
- 1988
- 1987
- 1982
- 1981
- 1955
Program
- All
- Executive (0)
- Healthy Mothers, Healthy Babies (HMHB) (0)
- Towards Eliminating HIV (8)
- Strategic Funding & Partnerships Executive Team (0)
- Disease Elimination (80)
- Maternal, Child and Adolescent Health (58)
- Philanthropy and Supporter Engagement (0)
- Health Security and Pandemic Preparedness (35)
- Eliminate Malaria (7)
- Eliminate Tuberculosis (TB) (6)
- Finance (0)
- Healthy Ageing (1)
- Human Resources (0)
- Burnet Honorary Research Fellows (1)
- Research Support and Facilities (0)
- Harm Reduction (31)
- Information Technology (0)
- Burnet Vaccine Initiative (0)
- Laboratory Services (0)
- Eliminate Viral Hepatitis (10)
- Education & Training (0)
- Infectious Diseases Elimination (2)
- Support Services Group (0)
- Project Management and Quality Assurance Office (0)
- Marketing and Communications (0)
- International Operations (0)
- Commercialisation, Innovation and Industry Partnerships (0)
Discipline
- All
- Life Sciences (0)
- Public Health (0)
- International Development (0)
Research Theme
- All
- HIV and AIDS (9)
- Sexually Transmitted Infections (STIs) (3)
- Maternal and Child Health (20)
- Malaria (7)
- Immune Disease and Cancer (1)
- Hepatitis B (4)
- Hepatitis C (9)
- Global infectious disease threats (1)
- Injecting Drug Use (17)
- Alcohol and Other Drugs (21)
- Tuberculosis (TB) (6)
- Young People's Health (3)
- Justice Health (5)
- Sexual and Reproductive Health (4)
- Infectious Disease Modelling (5)
- LGBTQIA+ (1)
- Global Adolescent Health (2)
- COVID-19 (novel coronavirus) (13)
